Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
about
Autophagy in thyroid cancer: present knowledge and future perspectivesUpdate: the status of clinical trials with kinase inhibitors in thyroid cancerUtility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer CellsPreclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinomamTOR pathway in colorectal cancer: an update.Genetics and epigenetics of sporadic thyroid cancer.PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.Effects of roniciclib in preclinical models of anaplastic thyroid cancer.High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na131I/5-FC on human thyroid cancer.
P2860
Q28086785-19359B22-D84A-4B94-AEBC-DBD82E228BEBQ33570056-505BC7BC-58A5-413A-882F-81151FCE2BABQ35025521-B6324868-C76B-4D4A-848B-462F46469480Q36282782-F3F915BE-DBCB-430E-B76E-A4CA733475D6Q36909931-430852F0-AD35-49DB-8621-1654A989ACA8Q37096469-3BFBB8C7-E24B-4BDA-8800-203EDC51E333Q37649634-7425C742-6283-4F22-B0C0-DEF959290020Q38128097-0406E201-FC65-4B1E-9F7F-E272CD34316BQ38239229-2EF2207E-63FB-4279-A8D7-AD234566BF07Q38644584-87D04F97-EFA9-4D85-A016-35F7E7BB6D75Q38704670-697CDA11-7AD5-438C-B1EB-06F1DE9484E0Q39735209-69915A43-5D02-4A12-B4FE-DEC6374944F0Q41582917-B32B24F7-448B-4545-8C63-F1B5D4C40FBAQ42366591-13A4D7D0-C2BE-48AD-BC8A-2113A7316C21Q46952217-C7119927-44C6-4722-8B6C-5B6667BA9F5BQ49207200-5F3DCFC0-9F3C-443B-9F68-44372F8D41AD
P2860
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
@ast
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
@en
Utility of a PI3K/mTOR inhibitor
@nl
type
label
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
@ast
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
@en
Utility of a PI3K/mTOR inhibitor
@nl
prefLabel
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
@ast
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
@en
Utility of a PI3K/mTOR inhibitor
@nl
P2093
P2860
P1433
P1476
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy
@en
P2093
Jen-Der Lin
Richard J Wong
Shu-Fu Lin
Ting-Chao Chou
P2860
P304
P356
10.1371/JOURNAL.PONE.0046726
P407
P577
2012-10-15T00:00:00Z